Skip to main content

Getting mental health diagnoses right without undermining access to care and disability rights

The UK government’s forthcoming review of mental health and neurodevelopmental diagnoses presents an opportunity to improve the healthcare and benefits system if the potential risks are averted. Rising rates of conditions such as ADHD, autism, and anxiety disorders have raised questions about whether we are seeing a genuine increase in need or greater awareness and possible over-diagnosis. A thoughtful, evidence-based review could help bring much-needed clarity. But if mishandled, it could deepen inequalities and undermine support for those who need it most.

Done well, the review could improve diagnostic quality and reduce the postcode lottery that too often defines access to assessment and treatment. Clearer clinical standards and properly funded services would allow professionals to make more accurate diagnoses, shorten long waiting lists, and better match interventions to individuals’ needs. This is an outcome everyone should welcome.

But the review must not become a vehicle for restricting access to treatment, reasonable adjustments, or disability benefits. The increase in diagnosed mental-health and neurodevelopmental conditions reflects, in large part, years of unmet need and increasing public willingness to seek help. Tightening diagnostic thresholds or narrowing eligibility criteria risks penalising individuals who already face significant barriers to care, particularly those from disadvantaged communities. It also risks pushing desperate families towards unregulated private providers.

Framing this issue as one of “too many diagnoses” is unhelpful. It risks stigmatising people who are already struggling and undermines recent progress in public understanding of neurodiversity and mental health. The question we should be asking is not “How do we reduce the numbers?” but “How do we ensure people receive timely, appropriate and equitable support?”

If the government wants to improve outcomes, the path forward is clear: strengthen diagnostic pathways, expand clinical capacity, invest in multidisciplinary teams, and safeguard the rights and protections that enable people to live well. Any attempt to use the review as justification for cuts, gatekeeping, or narrowing access would be a profound step backwards.

A better mental health system is one that supports people — not one that seeks to reduce the number who qualify for support. The review should be a catalyst for improvement, not an excuse for limiting care.

Comments

Popular posts from this blog

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...

The Hidden Cost of Cheaper NHS Contracts: Losing Community Trust

NHS budgets are under considerable pressure. It is therefore unsurprising that many NHS Integrated Care Boards (ICBs) In England will aim to prioritise price in contract awards, But this approach is a significant threat to community-centred healthcare. While competitive tendering is a legally required, an excessive focus on costs in awarding NHS contracts risks overshadowing key factors such as established community trust, local expertise, and the long-term impact on continuity of care. This shift towards cheaper, often external, commercial providers threatens to cut the links between communities and their local health services. The argument that competitive tendering is solely about legal compliance, and not cost, is undermined by the very nature of such tendering, which by design encourages the lowest bid. This approach risks eroding the social fabric of local healthcare provision, where established relationships and understanding of specific community needs are essential. Establishe...

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...